Miramoon Pharma's Eye Drop Clears a Preclinical Path for Retinitis Pigmentosa

For the more than two million people worldwide with retinitis pigmentosa, the standard of care has long been a slow, inevitable loss of vision. There is no approved therapy that halts the underlying cellular degeneration, a process driven by calcium dysregulation that kills photoreceptor cells. Miramoon Pharma, a small spinout from the University of the Basque Country, is betting its novel small molecule can change that, not by targeting a single genetic mutation, but by stabilizing the cellular machinery that fails across hundreds of them [AseBio, Nov 2025].

A platform built on calcium stabilization

The company's scientific wedge is a class of compounds designed to modulate FKBP12, a protein that regulates ryanodine receptor (RyR) channels. In simple terms, these channels control calcium release within cells, and in retinitis pigmentosa, they become leaky. This calcium overload is a final common pathway to cell death, occurring regardless of which of the more than 350 known causative genes is defective [Biotech Spain, Unknown]. Miramoon's lead candidate, MP-004, is formulated as a topical eye drop. Preclinical data in mouse models, published in Investigative Ophthalmology & Visual Science, shows the treatment can improve both retinal function and structure, suggesting it may preserve vision [IOVS | ARVO Journals, Unknown]. The asset has already secured Orphan Drug Designation from both the FDA and the European Medicines Agency, a critical regulatory milestone that provides development incentives and market exclusivity upon approval [AseBio, Nov 2025].

The long road from lab to clinic

Miramoon's current position is emblematic of early-stage biotech: promising science, regulatory recognition, but the immense risk and cost of clinical development still ahead. The company is completing pre-IND (Investigational New Drug) studies and aims to initiate its first clinical trial in 2026 [SPRI, Unknown]. Its business model, common for capital-efficient platforms, is to advance molecules to a point of de-risked value before seeking licensing or co-development deals with larger pharmaceutical partners [Miramoon Pharma website, Unknown]. The pipeline extends beyond ophthalmology, with four additional programs in lead nomination targeting Duchenne muscular dystrophy, myotonic dystrophy type 1, ALS, and Alzheimer's disease [Miramoon Pharma website, Unknown].

Leadership and funding reflect its academic origins and regional focus. CEO Amalia Capilla brings over two decades of molecular biology and biotech experience in Spain and the US [BStartup Banco Sabadell, Unknown]. The company is a consortium effort with several Spanish academic institutions, including the University of Barcelona and the Margarita Salas Biological Research Centre [Biotech Spain, Unknown]. Financially, it operates with the opacity typical of many European spinouts. While investment rounds have been led by Spanish firms BStartup10 and Pinama Capital, specific amounts and dates are not publicly disclosed [Capital-Riesgo.es, Unknown]. An industry database estimates its valuation at approximately $3.3 million, though this figure is unverified [Prospeo, Unknown].

Where the bet must prove itself

The path forward is lined with both scientific promise and formidable hurdles. The company's broad-platform approach is its core strength, potentially offering a treatment for a genetically heterogeneous disease, but also its central risk. The biology of calcium signaling is complex and interconnected; demonstrating a clean safety profile and clear efficacy in humans will be the ultimate test. Furthermore, the competitive landscape, while not yet crowded with disease-modifying therapies, includes other biotechs like Nacuity Pharmaceuticals and SparingVision exploring different mechanisms. Miramoon's success will hinge on three critical, sequential validations:

• Clinical translation. Moving from compelling mouse data to positive human trial results is the single greatest point of failure for any preclinical biotech. The 2026 trial will be the first real indicator.
• Funding runway. Advancing even a single asset through clinical trials requires tens of millions of euros. The undisclosed seed funding suggests a need for a substantial Series A in the near term to finance the clinic.
• Partner interest. For a company built on a licensing-out model, attracting a credible pharmaceutical partner after Phase 1 or Phase 2 data will be the key commercial inflection point.

For patients with retinitis pigmentosa, the current standard of care is largely supportive. It involves low-vision aids, genetic counseling, and managing associated conditions like cataracts. The only approved gene therapy, Luxturna, addresses a specific RPE65 mutation and applies to a tiny fraction of the patient population. The vast majority have no therapeutic option to slow the progression of their disease. Miramoon's bet is that by targeting a downstream, convergent mechanism of cell death, its eye drop could become a foundational treatment for a much broader group. The next eighteen months, as it files its IND and administers its first dose to a human patient, will determine if that bet has legs.

Sources

1. [AseBio, Nov 2025] Miramoon Pharma Breakthrough: Two Lead Candidates Show Promise | https://www.asebio.com/en/news-events/news/miramoon-pharma-breakthrough-two-lead-candidates-show-promise-prestigious
2. [Biotech Spain, Unknown] Miramoon Pharma company description | https://www.miramoonpharma.com/
3. [IOVS | ARVO Journals, Unknown] Topical administration of MP-004 improves retinal function and structure in a mouse model of retinitis pigmentosa. | https://iovs.arvojournals.org/article.aspx?articleid=2789757
4. [SPRI, Unknown] Reference to clinical trial plans | https://capital-riesgo.es/en/articles/bstartup10-leads-an-investment-round-in-miramoon-pharma/
5. [Miramoon Pharma website, Unknown] Company business model and pipeline | https://www.miramoonpharma.com/
6. [BStartup Banco Sabadell, Unknown] Profile of CEO Amalia Capilla | https://bstartup.bancsabadell.com/bstartup10-lidera-una-ronda-de-inversion-en-miramoon-pharma/
7. [Capital-Riesgo.es, Unknown] BStartup10 leads an investment round in Miramoon Pharma | https://capital-riesgo.es/en/articles/bstartup10-leads-an-investment-round-in-miramoon-pharma/
8. [Prospeo, Unknown] Estimated valuation data | https://pitchbook.com/profiles/company/493207-30